UCK2 Antibody

What is UCK2 and why is it important in cellular metabolism?

UCK2 (Uridine-Cytidine Kinase 2) catalyzes the phosphorylation of uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), respectively. This represents the first critical step in the production of pyrimidine nucleoside triphosphates required for RNA and DNA synthesis . UCK2 belongs to the uridine kinase family and plays important roles in pyrimidine salvage pathways. Unlike its homolog UCK1, UCK2 demonstrates tissue-specific expression patterns and has been implicated in various pathological processes, particularly in cancer progression .

How do I select the most appropriate UCK2 antibody for my research?

Selection should be based on:

• Application compatibility: Verify validated applications (WB, IHC, ICC, ELISA, IP) listed in product documentation

• Species reactivity: Confirm reactivity with your experimental model (human, mouse, rat, etc.)

• Epitope specificity: Consider whether N-terminal (AA 1-30), C-terminal (AA 227-255), or full-length (AA 1-261) targeting is most appropriate for your research question

• Clonality: Determine whether polyclonal (broader epitope recognition) or monoclonal (single epitope specificity) antibodies best suit your needs

• Validation data: Review published literature citing specific antibody clones and examine manufacturer validation data

What is the difference between UCK1, UCK2, and UCKL-1 antibodies?

These antibodies target distinct but related proteins:

• UCK1 antibodies: Target the constitutively expressed isoform found in most tissues

• UCK2 antibodies: Target the tissue-specific isoform (particularly in placenta and tumors) with observed molecular weight of 33-35 kDa (calculated 29 kDa)

• UCKL-1 antibodies: Target a less characterized family member with sequence similarity to UCK1/UCK2

Importantly, these antibodies demonstrate high specificity with minimal cross-reactivity. As confirmed by immunoblot analysis, antibodies against UCKL-1 show no cross-reactivity with UCK2, and antibodies against UCK2 show no cross-reactivity against UCKL-1 .

How is UCK2 implicated in cancer progression?

UCK2 has been identified as significantly overexpressed in multiple cancer types:

Mechanistically, UCK2 promotes cancer progression through:

• Activation of the PI3K/AKT/mTOR signaling pathway

• Inhibition of autophagy in tumor cells

• Interaction with EGFR to inhibit EGF-induced EGFR ubiquitination and degradation

• Enhancement of tumor cell proliferation and metastasis

How can UCK2 antibodies be used to assess patient prognosis in cancer research?

UCK2 antibodies can be employed in multiple methodologies for prognostic assessment:

• Immunohistochemistry (IHC):

  • Score UCK2 expression by multiplying percentage of immunopositive areas (0-4) and immunostaining intensity (0-3)

  • Define high expression as scores ≥4 and low expression as scores <3

  • Correlate with clinical parameters (T stage, N stage, recurrence probability)

• Western blot analysis:

  • Quantify UCK2 protein levels in tumor samples relative to normal tissues

  • Analyze association with survival metrics (OS, PFS, RFS)

• Tissue microarray analysis:

  • Evaluate UCK2 expression across large patient cohorts

  • Perform survival analysis stratifying by high vs. low UCK2 expression

What are the optimal conditions for UCK2 antibody use in Western blotting?

For optimal Western blot results:

• Sample preparation:

  • Extract total protein using RIPA buffer with protease inhibitors

  • Load 20-50 μg protein per lane

• Dilution factors:

  • Primary antibody: 1:500-1:2000 dilution

  • Secondary antibody: 1:5000-1:10000 HRP-conjugated anti-rabbit/mouse IgG

• Incubation conditions:

  • Primary antibody: Overnight at 4°C

  • Secondary antibody: 1 hour at room temperature

• Expected molecular weight: 33-35 kDa (calculated 29 kDa)

• Positive controls: Jurkat cells show reliable UCK2 expression

How can I optimize immunohistochemistry protocols for UCK2 detection in tissue samples?

For effective IHC staining:

• Tissue preparation:

  • Fix in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-5 μm thickness

• Antigen retrieval:

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Heat at 95-100°C for 15-20 minutes

• Staining protocol:

  • Block endogenous peroxidase with 1% hydrogen peroxide

  • Incubate with primary UCK2 antibody overnight at 4°C

  • Treat with biotinylated secondary antibody for 1 hour at room temperature

  • Visualize with 3,3-diaminobenzidine (DAB) and counterstain with hematoxylin

• Scoring system:

  • Calculate total score (0-12) by multiplying percentage of immunopositive areas (0-4) and immunostaining intensity (0-3)

  • Define high expression as scores ≥4; low expression as scores <3

What are the methodological considerations for immunoprecipitation using UCK2 antibodies?

For successful IP experiments:

• Antibody amount: Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

• Pre-clearing step:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation before adding UCK2 antibody

• Incubation conditions:

  • Mix antibody with lysate overnight at 4°C with gentle rotation

  • Add pre-washed protein A/G beads and incubate for additional 4 hours

• Washing stringency:

  • Perform 4-5 washes with IP buffer containing appropriate salt concentration

  • Consider detergent concentration based on interaction strength

• Controls:

  • Include IgG control to assess non-specific binding

  • Verify specificity using cell lines with UCK2 knockdown/knockout

How can UCK2 antibodies be employed in studying chemoresistance mechanisms in cancer?

UCK2 antibodies can be instrumental in investigating chemoresistance through:

• Expression analysis in resistant vs. sensitive cells:

  • Compare UCK2 levels in cisplatin-resistant vs. cisplatin-sensitive cells using Western blot

  • Correlate UCK2 expression with IC50 values for various chemotherapeutics

• Mechanistic studies:

  • Examine UCK2-mediated activation of PI3K/AKT/mTOR pathway in resistant cells

  • Investigate UCK2's role in autophagy inhibition using autophagy markers (LC3, p62)

  • Analyze EGFR stabilization by co-immunoprecipitation of UCK2 with EGFR

• Therapeutic targeting:

  • Monitor UCK2 expression changes following treatment with pathway inhibitors

  • Assess synergistic effects of UCK2 inhibition with conventional chemotherapy

Research has demonstrated that UCK2 overexpression desensitizes intrahepatic cholangiocarcinoma to cisplatin in both in vivo and in vitro models, and the mechanism involves autophagy inhibition through PI3K/AKT/mTOR pathway activation .

What approaches can be used to investigate UCK2 interaction with other proteins?

Several methodologies can be employed:

• Co-immunoprecipitation (Co-IP):

  • Perform pulldown with UCK2 antibody followed by Western blot for suspected interaction partners

  • Verify interactions with reverse Co-IP (pull down with partner antibody, blot for UCK2)

  • Use appropriate controls to rule out non-specific binding

• Proximity ligation assay (PLA):

  • Detect protein-protein interactions in situ with subcellular resolution

  • Visualize interactions between UCK2 and partners (e.g., EGFR) in fixed cells/tissues

• Bimolecular fluorescence complementation (BiFC):

  • Fuse UCK2 and potential partner to complementary fragments of fluorescent protein

  • Observe reconstituted fluorescence upon protein interaction

Research has shown that UCK2 interacts with EGFR to inhibit EGF-induced EGFR ubiquitination and degradation, resulting in increased EGFR stability and sustained activation of the EGFR-AKT pathway in hepatocellular carcinoma .

How can I distinguish between metabolic and non-metabolic functions of UCK2 in my research?

This requires specialized approaches:

• Enzymatic activity assays:

  • Measure UCK2 kinase activity using purified protein and substrates (uridine/cytidine)

  • Compare wildtype UCK2 with catalytically inactive mutants

• Structure-function analysis:

  • Generate UCK2 mutants that maintain structural integrity but lack catalytic activity

  • Assess which cellular phenotypes require enzymatic activity versus protein-protein interactions

• Metabolic profiling:

  • Use metabolomics to quantify pyrimidine metabolites in cells with UCK2 manipulation

  • Employ isotope tracing to track metabolic flux through UCK2-dependent pathways

Research has demonstrated that while UCK2's kinase activity is required for promoting cell proliferation, it is dispensable for UCK2-induced metastasis in hepatocellular carcinoma, suggesting distinct metabolic and non-metabolic functions .

What are common causes of non-specific binding with UCK2 antibodies and how can they be addressed?

Several factors can contribute to non-specific binding:

How do I interpret contradictory UCK2 expression data between different detection methods?

When facing contradictory results:

• Antibody validation:

  • Verify antibody specificity using positive controls (e.g., Jurkat cells)

  • Include UCK2 knockdown/knockout controls to confirm specificity

  • Check if different antibodies target different UCK2 epitopes that may be differentially accessible

• Methodological considerations:

  • mRNA vs. protein discrepancies may reflect post-transcriptional regulation

  • IHC vs. Western blot differences may indicate spatial heterogeneity in tissues

  • Consider sensitivity differences between methods (WB may detect lower expression levels)

• Biological variables:

  • Assess if cell culture conditions affect UCK2 expression

  • Consider tissue-specific expression patterns

  • Evaluate impact of tumor heterogeneity and sampling bias

What statistical approaches are recommended for analyzing UCK2 expression data in clinical samples?

For robust statistical analysis:

• Expression correlation with clinical parameters:

  • Chi-square test to analyze association between UCK2 expression and clinicopathological features

  • Mann-Whitney U test for comparison between two independent groups

  • Kruskal-Wallis test for comparison across multiple groups

• Survival analysis:

  • Kaplan-Meier method with log-rank test to compare survival outcomes between high and low UCK2 expression groups

  • Cox proportional hazards regression for univariate and multivariate analysis of prognostic factors

  • Consider time-dependent ROC analysis to determine optimal cut-off values

• Diagnostic accuracy assessment:

  • Calculate sensitivity, specificity, and diagnostic accuracy

  • Determine area under ROC curve (AUC) for diagnostic potential (values >0.9 indicate excellent diagnostic capacity)

  • Perform stratified analysis for specific cancer stages (e.g., early-stage cancer)

Studies have shown that UCK2 has significant diagnostic accuracy in lung cancer with AUC = 0.965 (95% CI = 0.9326-0.9974; P < 0.0001) and maintains high diagnostic value even in stage IA lung cancer with AUC = 0.9281 (95% CI = 0.8411-1.015; P < 0.0001) .